Sunday 5 August 2018

Malignant Mesothelioma Advances in Pathogenesis, Diagnosis, and Translational Therapies

Malignant Mesothelioma Advances in Pathogenesis, Diagnosis, and Translational Therapies by Harvey I. Pass, MD , Nicholas J. Vogelzang, MD, Michele Carbone, MD, PhD

Malignant mesothelioma remains one of the sentinel malignancies of oncology. It has a breathtakingly rapid natural  history with a median survival of 6 to 8 months when untreated, is environmentally related, and has such economic and social impact that  attorneys specialize in representing only mesothelioma patients. Expert  witnesses devote full time to testifying, and governments are  forced to consider not only the banning of the environmental agent but also  a reappraisal of the whole tort system for compensation to injured  victims. Furthermore, its presence in certain populations has changed the mindset of whole communities, such as Libby, Montana,  Cappadocia, Turkey, Sarnia, and Ontario.

1 The History of Mesothelioma
2 Asbestos-Induced Mesotheliom
3 SV40-Mediated Oncogenesis
4 Mesothelioma Carcinogenesis
5 Mesothelial and Mesothelioma Cell Lines
6 Cytogenetics of Malignant Mesothelioma
7 Growth Factors and Malignant Mesothelioma
8 Oncogenes and Tumor Suppressor Genes in
9 Malignant Mesothelioma
10 Angiogenesis and Mesothelioma
11 Immune Status and Mesothelioma
12 Extracellular Matrix and Mesothelioma: Some 13 Clues to the Invasive Behavior of Mesothelioma
14 Genomics and Proteomics in Mesothelioma
15 Asbestos Mineralogy and Health Effects Molecular Epidemiology of Mesothelioma  Malignant  Mesothelioma and Erionite
16 Determination of Asbestos Exposure
17 Clinical History
18 Mesothelioma and Asbestos Exposure From Monkey to Man: The Epidemiologic  Evidence of an Association Between Simian Virus 40 and Malignancy
19 Causes and Prevention of Technical Artifacts When Studying Simian Virus 40 (SV40)
20 Molecular Detection of Simian Virus 40 in Human Mesothelioma
21 Malignant Mesothelioma Following Radiation  Contents

22 Genetics and Human Mesothelioma
23 Clinicians Approach to Mesothelioma
24 Clinical Presentation and Natural History of Mesothelioma: Pleural and Pericardial
25 Clinical Presentation and Natural History of Mesothelioma: Abdominal
26 Staging of Mesothelioma
27 Prognostic Factors in Mesothelioma
28 Radiologic Assessment of Mesothelioma
29 Endoscopic Imaging
30 Benign Mesotheliomas, Mesothelial Proliferations, and Their Possible Association with Asbestos  Exposure
31 Cytology of Malignant Mesothelioma
32 Immunohistochemistry  Malignant Mesothelioma Electron Microscopy
34 Rare Variants of Mesothelioma
35 Differentiating Sarcomas from Mesotheliomas 36 Diagnosis of Synovial Sarcoma of the Pleura and Differentiation from Malignant Mesothelioma
37 Pitfalls in the Diagnosis of Malignant Mesothelioma
38 Management of Benign Variants of Mesothelioma
39 First-Line Chemotherapy for Malignant Pleural Mesothelioma
40 Second-Line Chemotherapy
41 Treatment of Mesothelioma with Radiotherapy
42 Intrapleural Chemotherapy with and Without Surgery in Malignant Pleural Mesothelioma (MPM)
43 Management of Pleural Effusions in Mesothelioma
44 Preoperative Chemotherapy and Surgery45 Photodynamic Therapy for Pleural Mesothelioma
46 Surgery and Postoperative Radiotherapy  Contents

47 The Development of the Brigham and Women’s Multimodality Treatment Plan for Malignant  Pleural Mesothelioma: A Model for Improving the Treatment of Rare Diseases
48 Peritoneal Mesothelioma: The Columbia Experience
49 Surgery, Hyperthermic Chemoperfusion, and Postoperative Chemotherapy: The National Cancer Institute and Washington Hospital Center Experience
50 Pericardial and Tunica Vaginalis Mesothelioma
51 New Target Therapies for Malignant Mesothelioma
52 Gene Therapy for Malignant Pleural Mesothelioma Immunotherapeutic Approaches and Vaccination Strategies
54 Economic Aspects of Mesothelioma

Express Your Opinions in comments